Graves病患者治疗方式的使用模式、疗效与安全性:一项全国性人群研究
该研究基于美国OptumLabs®数据仓库,纳入2005至2013年4661例Graves病患者,其中60%接受抗甲状腺药物(ATD),33%接受放射性碘(RAI),6%接受手术。ATD成功率50%,RAI为93%,手术为99%;ATD失败的中位时间为6.8个月,RAI和手术为3个月。ATD不良反应发生率为12%,RAI为6%,手术为24%。
要点
- ATD是最常用治疗(60%),但成功率最低(50%),RAI为93%,手术为99%。
- ATD治疗失败的中位时间为6.8个月,RAI和手术均为3个月。
- ATD不良反应发生率为12%,RAI为6%,手术为24%。
核心结论
- ATD是最常见的Graves病治疗方式,疗效最低,但严重不良反应不常见。
- 约四分之一患者仍在接受ATD治疗(初始或二线),有必要明确该治疗方式的长期疗效、安全性、费用和负担。
研究设计与样本
- 基于美国OptumLabs®数据仓库的全国性人群研究,纳入2005至2013年接受ATD、RAI或手术的Graves病患者。
- 共识别4661例患者,平均年龄48岁(SD ±14),白人63%,女性80%。
主要发现
- 患者接受ATD n=2817(60%)、RAI n=1549(33%)、手术 n=295(6%)。
- 成功率:ATD 50%,RAI 93%,手术 99%。
- 治疗失败的中位时间:ATD 6.8个月,RAI和手术均为3个月。
- 要求ATD治疗至少一年后再评估失败时,失败率降至25%。
- 不良反应发生率:ATD 12%,RAI 6%,手术 24%。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Background: Considerable uncertainty remains about the pattern of use of treatment options for Graves' disease (GD) and their comparative effectiveness and safety. Methods: Between 2005 and 2013, we identified patients with GD who received antithyroid drugs (ATDs), radioactive iodine (RAI) or surgery, and were represented in a large administrative data set in the United States (OptumLabs® Data Warehouse). Results: We identified 4661 patients with GD: mean age 48 (SD ±14) years, white (63%), and female (80%). Patients received ATD, n = 2817 (60%), RAI, n = 1549 (33%), or surgery, n = 295 (6%). Success rates were 50% for ATD, 93% for RAI, and 99% for surgery. Median time to treatment failure was 6.8 months for ATD and 3 months for RAI and surgery. When patients were required to be on ATD for at least one year before assessing failure, the failure rate decreased to 25%. Adverse effects occurred in 12% of patients receiving ATD, 6% with RAI, and 24% with surgery. Factors associated with treatment success were age >55 years (for ATD) and female sex (for RAI). About 12% of patients receiving ATD continued this treatment for >24 months as initial therapy. When patients failed ATD therapy, the most common second-line therapy was reinitiation of ATD (65%), RAI (26%), and surgery (9%). Overall, 26% of patients remain on ATD therapy (combined first or second line). Conclusions: ATD therapy was the most common GD therapy and demonstrated the lowest efficacy and infrequent significant adverse effect profile. With one fourth of patients remaining on ATD treatment (initial or second modality treatment), it becomes imperative to determine the long-term efficacy, safety, costs, and burdens of this modality of treatment.
引用
- Brito JP, Payne S, Singh Ospina N, et al. Patterns of Use, Efficacy, and Safety of Treatment Options for Patients with Graves' Disease: A Nationwide Population-Based Study. Thyroid. 2020. PMID: 31973681. doi:10.1089/thy.2019.0132
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。